Page last updated: 2024-11-08

prinomastat

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

prinomastat: a diazepine-based hydroxamic acid inhibitor; matrix metalloproteinase (MMP) inhibitor; angiogenesis inhibitor; [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

prinomastat : A hydroxamic acid that is (3S)-N-hydroxy-2,2-dimethylthiomorpholine-3-carboxamide in which the hydrogen attached to the thiomorpholine nitrogen has been replaced by a [4-(pyridin-4-yloxy)phenyl]sulfonyl group. It is a selective inhibitor with of matrix metalloproteinases (MMPs) 2, 3, 9, 13, and 14. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID466151
CHEMBL ID75094
CHEBI ID138885
SCHEMBL ID115696
MeSH IDM0292629

Synonyms (52)

Synonym
CHEMBL75094 ,
kb-r-9896
10t6626frk ,
unii-10t6626frk
kb-r 9896
BB 0262022
ag-3354
ag-3362
ag-3340
prinomastat (usan/inn)
D03797
192329-42-3
ag 3340
3-thiomorpholinecarboxamide, n-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-, (3s)-
prinomastat
(3s)-2,2-dimethyl-4-[4-(4-pyridyloxy)phenyl]sulfonyl-thiomorpholine-3-carbohydroxamic acid
ag3340
(s)-2,2-dimethyl-4-((p-(4-pyridyloxy)phenyl)sulfonyl)-3-thiomorpholinecarbohydroxamic acid
3-thiomorpholinecarboxamide, n-hydroxy-2,2-dimethyl-4-((4-(4-pyridinyloxy)phenyl)sulfonyl)-, (s)-
prinomastat [usan:inn]
CHEBI:138885
(3s)-n-hydroxy-2,2-dimethyl-4-{[4-(pyridin-4-yloxy)phenyl]sulfonyl}thiomorpholine-3-carboxamide
prinomastatum
(s)-2,2-dimethyl-4-{[p-(4-pyridyloxy)phenyl]sulfonyl}-3-thiomorpholinecarbohydroxamic acid
(s)-n-hydroxy-2,2-dimethyl-4-(4-(pyridin-4-yloxy)phenylsulfonyl)thiomorpholine-3-carboxamide
bdbm50082556
2,2-dimethyl-4-[4-(pyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid hydroxyamide(prinomastat)
2,2-dimethyl-4-[4-(pyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid hydroxyamide
2,2-dimethyl-4-[4-(pyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid hydroxyamide(ag 3340)
(s)-2,2-dimethyl-4-[4-(pyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid hydroxyamide
AKOS000280753
(3s)-n-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide
pn0 ,
prinomastat [mi]
prinomastat [usan]
prinomastat [who-dd]
3-thiomorpholinecarboxamide, n-hydroxy-2,2-dimethyl-4-((4-(4-pyridinyloxy)phenyl)sulfonyl)-, (3s)-
prinomastat [inn]
gtpl6505
DB05100
SCHEMBL115696
DTXSID3043946
HY-12170
CS-7961
NCGC00485069-01
(s)-n-hydroxy-2,2-dimethyl-4-((4-(pyridin-4-yloxy)phenyl)sulfonyl)thiomorpholine-3-carboxamide
Q7245228
kb-r9896
MS-27439
EN300-7503678
(3s)-n-hydroxy-2,2-dimethyl-4-[4-(pyridin-4-yloxy)benzenesulfonyl]thiomorpholine-3-carboxamide
Z2724205456

Research Excerpts

Overview

Prinomastat is a matrix metalloprotease (MMP) inhibitor with selectivity for MMPs 2, 3, 9, 13, and 14.

ExcerptReferenceRelevance
"Prinomastat is a matrix metalloprotease (MMP) inhibitor with selectivity for MMPs 2, 3, 9, 13, and 14. "( Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor.
Alberti, D; Binger, K; Clendeninn, N; Collier, M; Dixon, M; Hande, KR; Paradiso, L; Stuart-Smith, J; Wilding, G; Yeun, G, 2004
)
2.04

Treatment

Prinomastat treatment at the 250 mg/kg/day dose produced a decrease in body weight and food consumption in the dams. Treatment with prinomastAT, intraperitoneally twice daily for 21 days, reduced primary tumor volume significantly to 19.0 (+/-7.7)% of control.

ExcerptReferenceRelevance
"Prinomastat treatment at the 250 mg/kg/day dose produced a decrease in body weight and food consumption in the dams. "( Inhibiting matrix metalloproteinases with prinomastat produces abnormalities in fetal growth and development in rats.
Jessen, BA; Stevens, GJ; Wu, EY; Younis, HS, 2006
)
2.04
"Treatment with prinomastat, intraperitoneally twice daily for 21 days, reduced primary tumor volume significantly to 19.0 (+/-7.7)% of control, with induction of necrosis, differentiation, and fibrotic tissue in the pancreatic tumors."( Inhibitory effect of a matrix metalloproteinase inhibitor on growth and spread of human pancreatic ductal adenocarcinoma evaluated in an orthotopic severe combined immunodeficient (SCID) mouse model.
Alves, F; Augustin, H; Borchers, U; Klöppel, G; Nebendahl, K; Padge, B; Tietze, LF, 2001
)
0.65

Pharmacokinetics

ExcerptReferenceRelevance
" Here we report pharmacokinetic and anti-tumor efficacy studies with a series of structurally related inhibitors of these enzymes that were synthesized at Agouron Pharmaceuticals using protein structure based drug design."( Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases.
Appelt, K; Daniels, RG; McDermott, CD; Santos, O, 1997
)
0.3
" The Cmax of these regimens was 83 +/- 43, 287 +/- 175 and 462 +/- 495 ng/ml, respectively."( Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations.
Appelt, K; Brekken, J; Kolis, S; Shalinsky, DR; Webber, S; Wood, A; Zou, H,
)
0.13

Bioavailability

ExcerptReferenceRelevance
" Rat oral bioavailability ranged from 15 to 68%."( Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases.
Appelt, K; Daniels, RG; McDermott, CD; Santos, O, 1997
)
0.3
" The hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analogue marimastat, which bind covalently to the zinc atom at the MMP-active site, were the first MMP inhibitors to be studied in detail."( Development of matrix metalloproteinase inhibitors in cancer therapy.
Eckhardt, SG; Hidalgo, M, 2001
)
0.31
" Optimization of the substituent adjacent to the retrohydroxamate center in this series led to the clinical candidate ABT-518 (6), a highly potent, selective, orally bioavailable MMP inhibitor that has been shown to significantly inhibit tumor growth in animal cancer models."( Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
Albert, DH; Bouska, JJ; Curtin, ML; Dai, Y; Davidsen, SK; Elmore, IN; Florjancic, AS; Garland, RB; Goodfellow, CL; Guo, Y; Heyman, HR; Holms, JH; Marcotte, PA; Michaelides, MR; Morgan, DW; Stacey, JR; Steinman, DH; Tapang, P; Wada, CK, 2002
)
0.31
" Since the discovery of anti-TNF-alpha biologicals, much efforts have gone into developing an orally bioavailable small size TNF-alpha antagonist."( Current perspective of TACE inhibitors: a review.
DasGupta, S; Giridhar, R; Murumkar, PR; Yadav, MR, 2009
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
") and oral dosing in mice."( Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials.
Appelt, K; Bender, S; Brekken, J; Edwards, D; Forsyth, P; Margosiak, S; McDermott, CD; Shalinsky, DR; Truitt, G; Varki, NM; Wood, A; Zou, H, 1999
)
0.3
" AUC(0-24 h) values estimated from dosing with 25 and 200 mg/kg/day AG3340 were 672 and 10882 ng*h/ml, respectively."( Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations.
Appelt, K; Brekken, J; Kolis, S; Shalinsky, DR; Webber, S; Wood, A; Zou, H,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
matrix metalloproteinase inhibitornull
EC 3.4.24.35 (gelatinase B) inhibitorAn EC 3.4.24.* (metalloendopeptidase) inhibitor that interferes with the action of gelatinase B (EC 3.4.24.35).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
hydroxamic acidA compound, RkE(=O)lNHOH, derived from an oxoacid RkE(=O)l(OH) (l =/= 0) by replacing -OH with -NHOH, and derivatives thereof. Specific examples of hydroxamic acids are preferably named as N-hydroxy amides.
thiomorpholines
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Interstitial collagenaseHomo sapiens (human)IC50 (µMol)0.02090.00020.850210.0000AID108733; AID108749; AID108758; AID108766; AID108894; AID109078; AID241638
Interstitial collagenaseHomo sapiens (human)Ki0.00820.00030.49487.0000AID104563; AID108922; AID108928
72 kDa type IV collagenaseHomo sapiens (human)IC50 (µMol)0.00050.00001.284810.0000AID107159; AID107168; AID107172; AID107333; AID109581; AID1609033; AID241639
72 kDa type IV collagenaseHomo sapiens (human)Ki0.00010.00000.34663.0000AID107178; AID107182; AID107185; AID107316
Stromelysin-1Homo sapiens (human)IC50 (µMol)0.00220.00001.148410.0000AID107361; AID107502; AID107514; AID107675; AID241640
Stromelysin-1Homo sapiens (human)Ki0.00030.00030.54258.0000AID107525; AID107532
MatrilysinHomo sapiens (human)IC50 (µMol)0.07230.00142.085910.0000AID107693; AID107840; AID241641
MatrilysinHomo sapiens (human)Ki0.05400.05401.50527.0000AID104909
Matrix metalloproteinase-9Homo sapiens (human)IC50 (µMol)0.00070.00000.705310.0000AID108008; AID108140; AID108147; AID108303; AID1609034; AID241643
Neutrophil collagenaseHomo sapiens (human)IC50 (µMol)0.00050.00000.927210.0000AID107847; AID107991
Collagenase 3Homo sapiens (human)IC50 (µMol)0.00080.00000.767510.0000AID109250; AID109264; AID109382; AID109384; AID109417
Collagenase 3Homo sapiens (human)Ki0.00000.00000.47593.8000AID109387; AID109390
Melatonin receptor type 1AGallus gallus (chicken)IC50 (µMol)0.00490.00490.00490.0049AID107361
Melatonin receptor type 1CGallus gallus (chicken)IC50 (µMol)0.00490.00490.00490.0049AID107361
Matrix metalloproteinase-14Homo sapiens (human)IC50 (µMol)0.00030.00030.718210.0000AID241672
Melatonin receptor type 1BGallus gallus (chicken)IC50 (µMol)0.00490.00490.00490.0049AID107361
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)IC50 (µMol)8.31100.00021.014010.0000AID215604; AID347023
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Interstitial collagenaseHomo sapiens (human)Activity0.02350.00290.27550.8000AID108728
72 kDa type IV collagenaseHomo sapiens (human)Activity0.00030.00030.00050.0008AID109578
Collagenase 3Homo sapiens (human)Activity0.00050.00050.00100.0020AID109247
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (140)

Processvia Protein(s)Taxonomy
proteolysisInterstitial collagenaseHomo sapiens (human)
protein metabolic processInterstitial collagenaseHomo sapiens (human)
extracellular matrix disassemblyInterstitial collagenaseHomo sapiens (human)
collagen catabolic processInterstitial collagenaseHomo sapiens (human)
positive regulation of protein-containing complex assemblyInterstitial collagenaseHomo sapiens (human)
cellular response to UV-AInterstitial collagenaseHomo sapiens (human)
extracellular matrix organizationInterstitial collagenaseHomo sapiens (human)
angiogenesis72 kDa type IV collagenaseHomo sapiens (human)
ovarian follicle development72 kDa type IV collagenaseHomo sapiens (human)
ovulation from ovarian follicle72 kDa type IV collagenaseHomo sapiens (human)
luteinization72 kDa type IV collagenaseHomo sapiens (human)
blood vessel maturation72 kDa type IV collagenaseHomo sapiens (human)
intramembranous ossification72 kDa type IV collagenaseHomo sapiens (human)
proteolysis72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of cell adhesion72 kDa type IV collagenaseHomo sapiens (human)
heart development72 kDa type IV collagenaseHomo sapiens (human)
embryo implantation72 kDa type IV collagenaseHomo sapiens (human)
parturition72 kDa type IV collagenaseHomo sapiens (human)
response to xenobiotic stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to mechanical stimulus72 kDa type IV collagenaseHomo sapiens (human)
peripheral nervous system axon regeneration72 kDa type IV collagenaseHomo sapiens (human)
response to activity72 kDa type IV collagenaseHomo sapiens (human)
protein metabolic process72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix disassembly72 kDa type IV collagenaseHomo sapiens (human)
protein catabolic process72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of cell migration72 kDa type IV collagenaseHomo sapiens (human)
collagen catabolic process72 kDa type IV collagenaseHomo sapiens (human)
response to retinoic acid72 kDa type IV collagenaseHomo sapiens (human)
cellular response to reactive oxygen species72 kDa type IV collagenaseHomo sapiens (human)
response to nicotine72 kDa type IV collagenaseHomo sapiens (human)
endodermal cell differentiation72 kDa type IV collagenaseHomo sapiens (human)
response to hydrogen peroxide72 kDa type IV collagenaseHomo sapiens (human)
response to estrogen72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of vasoconstriction72 kDa type IV collagenaseHomo sapiens (human)
ephrin receptor signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
macrophage chemotaxis72 kDa type IV collagenaseHomo sapiens (human)
response to electrical stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to hyperoxia72 kDa type IV collagenaseHomo sapiens (human)
face morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
bone trabecula formation72 kDa type IV collagenaseHomo sapiens (human)
prostate gland epithelium morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
cellular response to amino acid stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to interleukin-172 kDa type IV collagenaseHomo sapiens (human)
cellular response to estradiol stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to UV-A72 kDa type IV collagenaseHomo sapiens (human)
cellular response to fluid shear stress72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
response to amyloid-beta72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix organization72 kDa type IV collagenaseHomo sapiens (human)
response to hypoxia72 kDa type IV collagenaseHomo sapiens (human)
tissue remodeling72 kDa type IV collagenaseHomo sapiens (human)
proteolysisStromelysin-1Homo sapiens (human)
extracellular matrix disassemblyStromelysin-1Homo sapiens (human)
protein catabolic processStromelysin-1Homo sapiens (human)
regulation of cell migrationStromelysin-1Homo sapiens (human)
collagen catabolic processStromelysin-1Homo sapiens (human)
positive regulation of protein-containing complex assemblyStromelysin-1Homo sapiens (human)
cellular response to reactive oxygen speciesStromelysin-1Homo sapiens (human)
innate immune responseStromelysin-1Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionStromelysin-1Homo sapiens (human)
cellular response to lipopolysaccharideStromelysin-1Homo sapiens (human)
cellular response to amino acid stimulusStromelysin-1Homo sapiens (human)
cellular response to UV-AStromelysin-1Homo sapiens (human)
cellular response to nitric oxideStromelysin-1Homo sapiens (human)
regulation of neuroinflammatory responseStromelysin-1Homo sapiens (human)
response to amyloid-betaStromelysin-1Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processStromelysin-1Homo sapiens (human)
extracellular matrix organizationStromelysin-1Homo sapiens (human)
membrane protein ectodomain proteolysisMatrilysinHomo sapiens (human)
membrane protein intracellular domain proteolysisMatrilysinHomo sapiens (human)
antibacterial peptide secretionMatrilysinHomo sapiens (human)
antibacterial peptide biosynthetic processMatrilysinHomo sapiens (human)
proteolysisMatrilysinHomo sapiens (human)
response to xenobiotic stimulusMatrilysinHomo sapiens (human)
extracellular matrix disassemblyMatrilysinHomo sapiens (human)
positive regulation of cell migrationMatrilysinHomo sapiens (human)
collagen catabolic processMatrilysinHomo sapiens (human)
regulation of cell population proliferationMatrilysinHomo sapiens (human)
defense response to Gram-negative bacteriumMatrilysinHomo sapiens (human)
defense response to Gram-positive bacteriumMatrilysinHomo sapiens (human)
extracellular matrix organizationMatrilysinHomo sapiens (human)
skeletal system developmentMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of protein phosphorylationMatrix metalloproteinase-9Homo sapiens (human)
proteolysisMatrix metalloproteinase-9Homo sapiens (human)
apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
embryo implantationMatrix metalloproteinase-9Homo sapiens (human)
cell migrationMatrix metalloproteinase-9Homo sapiens (human)
extracellular matrix disassemblyMatrix metalloproteinase-9Homo sapiens (human)
macrophage differentiationMatrix metalloproteinase-9Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-9Homo sapiens (human)
cellular response to reactive oxygen speciesMatrix metalloproteinase-9Homo sapiens (human)
endodermal cell differentiationMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of DNA bindingMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
ephrin receptor signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of keratinocyte migrationMatrix metalloproteinase-9Homo sapiens (human)
cellular response to lipopolysaccharideMatrix metalloproteinase-9Homo sapiens (human)
cellular response to cadmium ionMatrix metalloproteinase-9Homo sapiens (human)
cellular response to UV-AMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaMatrix metalloproteinase-9Homo sapiens (human)
regulation of neuroinflammatory responseMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of receptor bindingMatrix metalloproteinase-9Homo sapiens (human)
response to amyloid-betaMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of epithelial cell differentiation involved in kidney developmentMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of cation channel activityMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of microglial cell activationNeutrophil collagenaseHomo sapiens (human)
proteolysisNeutrophil collagenaseHomo sapiens (human)
extracellular matrix disassemblyNeutrophil collagenaseHomo sapiens (human)
collagen catabolic processNeutrophil collagenaseHomo sapiens (human)
positive regulation of tumor necrosis factor productionNeutrophil collagenaseHomo sapiens (human)
endodermal cell differentiationNeutrophil collagenaseHomo sapiens (human)
cellular response to lipopolysaccharideNeutrophil collagenaseHomo sapiens (human)
positive regulation of neuroinflammatory responseNeutrophil collagenaseHomo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayNeutrophil collagenaseHomo sapiens (human)
extracellular matrix organizationNeutrophil collagenaseHomo sapiens (human)
endochondral ossificationCollagenase 3Homo sapiens (human)
growth plate cartilage developmentCollagenase 3Homo sapiens (human)
proteolysisCollagenase 3Homo sapiens (human)
extracellular matrix disassemblyCollagenase 3Homo sapiens (human)
bone mineralizationCollagenase 3Homo sapiens (human)
collagen catabolic processCollagenase 3Homo sapiens (human)
bone morphogenesisCollagenase 3Homo sapiens (human)
response to amyloid-betaCollagenase 3Homo sapiens (human)
extracellular matrix organizationCollagenase 3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayMelatonin receptor type 1AGallus gallus (chicken)
negative regulation of glycolytic processMelatonin receptor type 1AGallus gallus (chicken)
negative regulation of glucose importMelatonin receptor type 1AGallus gallus (chicken)
G protein-coupled receptor signaling pathwayMelatonin receptor type 1AGallus gallus (chicken)
negative regulation of glycolytic processMelatonin receptor type 1CGallus gallus (chicken)
negative regulation of glucose importMelatonin receptor type 1CGallus gallus (chicken)
G protein-coupled receptor signaling pathwayMelatonin receptor type 1CGallus gallus (chicken)
angiogenesisMatrix metalloproteinase-14Homo sapiens (human)
ovarian follicle developmentMatrix metalloproteinase-14Homo sapiens (human)
response to hypoxiaMatrix metalloproteinase-14Homo sapiens (human)
endothelial cell proliferationMatrix metalloproteinase-14Homo sapiens (human)
endochondral ossificationMatrix metalloproteinase-14Homo sapiens (human)
proteolysisMatrix metalloproteinase-14Homo sapiens (human)
response to oxidative stressMatrix metalloproteinase-14Homo sapiens (human)
male gonad developmentMatrix metalloproteinase-14Homo sapiens (human)
response to mechanical stimulusMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of myotube differentiationMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of protein processingMatrix metalloproteinase-14Homo sapiens (human)
response to organic cyclic compoundMatrix metalloproteinase-14Homo sapiens (human)
protein processingMatrix metalloproteinase-14Homo sapiens (human)
extracellular matrix disassemblyMatrix metalloproteinase-14Homo sapiens (human)
protein catabolic processMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of cell growthMatrix metalloproteinase-14Homo sapiens (human)
lung developmentMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of cell migrationMatrix metalloproteinase-14Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-14Homo sapiens (human)
zymogen activationMatrix metalloproteinase-14Homo sapiens (human)
endodermal cell differentiationMatrix metalloproteinase-14Homo sapiens (human)
chondrocyte proliferationMatrix metalloproteinase-14Homo sapiens (human)
astrocyte cell migrationMatrix metalloproteinase-14Homo sapiens (human)
response to estrogenMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of B cell differentiationMatrix metalloproteinase-14Homo sapiens (human)
negative regulation of Notch signaling pathwayMatrix metalloproteinase-14Homo sapiens (human)
embryonic cranial skeleton morphogenesisMatrix metalloproteinase-14Homo sapiens (human)
branching morphogenesis of an epithelial tubeMatrix metalloproteinase-14Homo sapiens (human)
tissue remodelingMatrix metalloproteinase-14Homo sapiens (human)
cell motilityMatrix metalloproteinase-14Homo sapiens (human)
negative regulation of focal adhesion assemblyMatrix metalloproteinase-14Homo sapiens (human)
head developmentMatrix metalloproteinase-14Homo sapiens (human)
craniofacial suture morphogenesisMatrix metalloproteinase-14Homo sapiens (human)
negative regulation of GDF15-GFRAL signaling pathwayMatrix metalloproteinase-14Homo sapiens (human)
regulation of protein localization to plasma membraneMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of macrophage migrationMatrix metalloproteinase-14Homo sapiens (human)
response to odorantMatrix metalloproteinase-14Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-14Homo sapiens (human)
skeletal system developmentMatrix metalloproteinase-14Homo sapiens (human)
G protein-coupled receptor signaling pathwayMelatonin receptor type 1BGallus gallus (chicken)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (25)

Processvia Protein(s)Taxonomy
endopeptidase activityInterstitial collagenaseHomo sapiens (human)
metalloendopeptidase activityInterstitial collagenaseHomo sapiens (human)
serine-type endopeptidase activityInterstitial collagenaseHomo sapiens (human)
peptidase activityInterstitial collagenaseHomo sapiens (human)
zinc ion bindingInterstitial collagenaseHomo sapiens (human)
fibronectin binding72 kDa type IV collagenaseHomo sapiens (human)
endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
metalloendopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
serine-type endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
protein binding72 kDa type IV collagenaseHomo sapiens (human)
metallopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
zinc ion binding72 kDa type IV collagenaseHomo sapiens (human)
endopeptidase activityStromelysin-1Homo sapiens (human)
metalloendopeptidase activityStromelysin-1Homo sapiens (human)
serine-type endopeptidase activityStromelysin-1Homo sapiens (human)
protein bindingStromelysin-1Homo sapiens (human)
peptidase activityStromelysin-1Homo sapiens (human)
metallopeptidase activityStromelysin-1Homo sapiens (human)
zinc ion bindingStromelysin-1Homo sapiens (human)
endopeptidase activityMatrilysinHomo sapiens (human)
metalloendopeptidase activityMatrilysinHomo sapiens (human)
serine-type endopeptidase activityMatrilysinHomo sapiens (human)
protein bindingMatrilysinHomo sapiens (human)
metallopeptidase activityMatrilysinHomo sapiens (human)
zinc ion bindingMatrilysinHomo sapiens (human)
endopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
serine-type endopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
protein bindingMatrix metalloproteinase-9Homo sapiens (human)
collagen bindingMatrix metalloproteinase-9Homo sapiens (human)
peptidase activityMatrix metalloproteinase-9Homo sapiens (human)
metallopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-9Homo sapiens (human)
identical protein bindingMatrix metalloproteinase-9Homo sapiens (human)
endopeptidase activityNeutrophil collagenaseHomo sapiens (human)
metalloendopeptidase activityNeutrophil collagenaseHomo sapiens (human)
serine-type endopeptidase activityNeutrophil collagenaseHomo sapiens (human)
peptidase activityNeutrophil collagenaseHomo sapiens (human)
zinc ion bindingNeutrophil collagenaseHomo sapiens (human)
tumor necrosis factor bindingNeutrophil collagenaseHomo sapiens (human)
endopeptidase activityCollagenase 3Homo sapiens (human)
metalloendopeptidase activityCollagenase 3Homo sapiens (human)
serine-type endopeptidase activityCollagenase 3Homo sapiens (human)
calcium ion bindingCollagenase 3Homo sapiens (human)
collagen bindingCollagenase 3Homo sapiens (human)
zinc ion bindingCollagenase 3Homo sapiens (human)
melatonin receptor activityMelatonin receptor type 1AGallus gallus (chicken)
hormone bindingMelatonin receptor type 1AGallus gallus (chicken)
melatonin bindingMelatonin receptor type 1AGallus gallus (chicken)
G protein-coupled receptor activityMelatonin receptor type 1AGallus gallus (chicken)
melatonin receptor activityMelatonin receptor type 1CGallus gallus (chicken)
melatonin bindingMelatonin receptor type 1CGallus gallus (chicken)
G protein-coupled receptor activityMelatonin receptor type 1CGallus gallus (chicken)
endopeptidase activityMatrix metalloproteinase-14Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-14Homo sapiens (human)
serine-type endopeptidase activityMatrix metalloproteinase-14Homo sapiens (human)
integrin bindingMatrix metalloproteinase-14Homo sapiens (human)
protein bindingMatrix metalloproteinase-14Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-14Homo sapiens (human)
metalloaminopeptidase activityMatrix metalloproteinase-14Homo sapiens (human)
melatonin receptor activityMelatonin receptor type 1BGallus gallus (chicken)
G protein-coupled receptor activityMelatonin receptor type 1BGallus gallus (chicken)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (31)

Processvia Protein(s)Taxonomy
extracellular regionInterstitial collagenaseHomo sapiens (human)
extracellular matrixInterstitial collagenaseHomo sapiens (human)
extracellular spaceInterstitial collagenaseHomo sapiens (human)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular region72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
nucleus72 kDa type IV collagenaseHomo sapiens (human)
mitochondrion72 kDa type IV collagenaseHomo sapiens (human)
plasma membrane72 kDa type IV collagenaseHomo sapiens (human)
sarcomere72 kDa type IV collagenaseHomo sapiens (human)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
extracellular regionStromelysin-1Homo sapiens (human)
nucleusStromelysin-1Homo sapiens (human)
mitochondrionStromelysin-1Homo sapiens (human)
cytosolStromelysin-1Homo sapiens (human)
extracellular matrixStromelysin-1Homo sapiens (human)
extracellular spaceStromelysin-1Homo sapiens (human)
extracellular regionMatrilysinHomo sapiens (human)
extracellular matrixMatrilysinHomo sapiens (human)
extracellular exosomeMatrilysinHomo sapiens (human)
extracellular spaceMatrilysinHomo sapiens (human)
extracellular regionMatrix metalloproteinase-9Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-9Homo sapiens (human)
collagen-containing extracellular matrixMatrix metalloproteinase-9Homo sapiens (human)
extracellular exosomeMatrix metalloproteinase-9Homo sapiens (human)
tertiary granule lumenMatrix metalloproteinase-9Homo sapiens (human)
ficolin-1-rich granule lumenMatrix metalloproteinase-9Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-9Homo sapiens (human)
extracellular regionNeutrophil collagenaseHomo sapiens (human)
extracellular spaceNeutrophil collagenaseHomo sapiens (human)
specific granule lumenNeutrophil collagenaseHomo sapiens (human)
collagen-containing extracellular matrixNeutrophil collagenaseHomo sapiens (human)
tertiary granule lumenNeutrophil collagenaseHomo sapiens (human)
extracellular spaceNeutrophil collagenaseHomo sapiens (human)
extracellular regionCollagenase 3Homo sapiens (human)
extracellular matrixCollagenase 3Homo sapiens (human)
extracellular spaceCollagenase 3Homo sapiens (human)
receptor complexMelatonin receptor type 1AGallus gallus (chicken)
plasma membraneMelatonin receptor type 1AGallus gallus (chicken)
nucleoplasmMelatonin receptor type 1CGallus gallus (chicken)
plasma membraneMelatonin receptor type 1CGallus gallus (chicken)
cytoplasmMatrix metalloproteinase-14Homo sapiens (human)
plasma membraneMatrix metalloproteinase-14Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-14Homo sapiens (human)
nucleusMatrix metalloproteinase-14Homo sapiens (human)
Golgi lumenMatrix metalloproteinase-14Homo sapiens (human)
cytosolMatrix metalloproteinase-14Homo sapiens (human)
plasma membraneMatrix metalloproteinase-14Homo sapiens (human)
focal adhesionMatrix metalloproteinase-14Homo sapiens (human)
extracellular matrixMatrix metalloproteinase-14Homo sapiens (human)
cytoplasmic vesicleMatrix metalloproteinase-14Homo sapiens (human)
melanosomeMatrix metalloproteinase-14Homo sapiens (human)
macropinosomeMatrix metalloproteinase-14Homo sapiens (human)
intermediate filament cytoskeletonMatrix metalloproteinase-14Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-14Homo sapiens (human)
plasma membraneMelatonin receptor type 1BGallus gallus (chicken)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (84)

Assay IDTitleYearJournalArticle
AID109264Inhibition of Matrix metalloprotease-132001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.
AID12487Half life period after intravenous administration at 20 mpk in rats2001Bioorganic & medicinal chemistry letters, Sep-17, Volume: 11, Issue:18
Selective, orally active MMP inhibitors with an aryl backbone.
AID215604Inhibition of TNF(tumor necrosis factor) in human blood1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.
AID108008Inhibition of gelatinase-B (Matrix metalloprotease-9)1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.
AID104563Inhibition of collagenase-1 (Matrix metalloprotease-1)1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.
AID109578Inhibitory concentration against Matrix metalloprotease-22001Bioorganic & medicinal chemistry letters, Sep-17, Volume: 11, Issue:18
Selective, orally active MMP inhibitors with an aryl backbone.
AID233119Relative affinity for MMP-3 over MMP-22004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.
AID107159Inhibition of Matrix metalloprotease-22001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.
AID13123Oral bioavailability in rat2001Bioorganic & medicinal chemistry letters, Sep-17, Volume: 11, Issue:18
Selective, orally active MMP inhibitors with an aryl backbone.
AID108733In vitro inhibitory activity against truncated collagenase-1 (matrix metalloprotease-1).1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.
AID108922Inhibition of matrix metalloprotease-1 (MMP-1).2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID241641Inhibition of human matrix metalloprotease-72005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.
AID108303In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
AID1609035Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
AID109390Inhibition of matrix metalloprotease-13 (MMP-13).2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID107525Inhibition of Matrix metalloprotease-31999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.
AID233121Selectivity factor, expressed as affinity at MMP-7 versus affinity at MMP-22004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.
AID10938250 percent inhibition of human Matrix metalloprotease-13 by the cleavage of fluorogenic peptide MCA-Pro-Leu-Gly-Leu-Dpa-ala-Arg-NH22000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and activity of selective MMP inhibitors with an aryl backbone.
AID108928Inhibition of human matrix metalloprotease-12004Journal of medicinal chemistry, May-20, Volume: 47, Issue:11
Receptor flexibility in the in silico screening of reagents in the S1' pocket of human collagenase.
AID241639Inhibition of human matrix metalloprotease-22005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.
AID1609040Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
AID10716850 percent inhibition of human Matrix metalloprotease-2 by the cleavage of fluorogenic peptide MCA-Pro-Leu-Gly-Leu-Dpa-ala-Arg-NH22000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and activity of selective MMP inhibitors with an aryl backbone.
AID233118Relative affinity for MMP-13 over MMP-22004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.
AID107316Inhibition of matrix metalloprotease-2 (MMP-2).2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID109250In vitro inhibitory activity against collagenase-3 (matrix metalloprotease-13).1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.
AID249409Ratio of IC50 value for MMP2 and MMP-32005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.
AID108728Inhibitory activity against human Matrix metalloprotease-12001Bioorganic & medicinal chemistry letters, Sep-17, Volume: 11, Issue:18
Selective, orally active MMP inhibitors with an aryl backbone.
AID241672Inhibition of human matrix metalloprotease-142005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.
AID109387Inhibition of collagenase (Matrix metalloprotease-13)1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.
AID241638Inhibition of human matrix metalloprotease-12005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.
AID109384Inhibitory activity against matrix metalloprotease-13 (MMP13)2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.
AID1609044Inhibition of cell invasion in human A549 cells at 1 to 10 uM incubated for 24 hrs by crystal violet staining based matrigel migration assay
AID241640Inhibition of human matrix metalloprotease-32005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.
AID107532Inhibition of matrix metalloprotease-3 (MMP-3).2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID1609034Inhibition of recombinant human MMP9 using thiopeptide as substrate preincubated for 30 mins followed by substrate addition and measured every min for 20 mins by colorimetric assay
AID107991Inhibition of Matrix metalloprotease-8 (MMP-8) in fluorimetric assay2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
AID107178Inhibition of Matrix metalloprotease-22004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.
AID249411Ratio of IC50 value for MMP2 and MMP92005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.
AID109417Inhibition of Matrix metalloprotease-13 (MMP-13) in fluorimetric assay2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
AID109247Inhibitory activity against human Matrix metalloprotease-132001Bioorganic & medicinal chemistry letters, Sep-17, Volume: 11, Issue:18
Selective, orally active MMP inhibitors with an aryl backbone.
AID107675Inhibition of Matrix metalloprotease-3 (MMP-3) in fluorimetric assay2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
AID109078In vitro selective inhibition against matrix metalloprotease-1 (MMP-1) using a fluorimetric assay2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
AID249415Ratio of IC50 valu for MMP2 and MMP142005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.
AID1609037Antiproliferative activity against human KG1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
AID107840Inhibition of Matrix metalloprotease-7 (MMP-7) in fluorimetric assay2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
AID347023Inhibition of TACE2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Current perspective of TACE inhibitors: a review.
AID107172Inhibitory activity against matrix metalloprotease-2 (MMP2)2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.
AID1609041Cytotoxicity against HUVEC assessed as reduction in cell viability incubated for 48 hrs by MTT assay
AID107514Inhibitory activity against matrix metalloprotease-3 (MMP3)2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.
AID11415Cmax after oral administration at 20 mpk in rats2001Bioorganic & medicinal chemistry letters, Sep-17, Volume: 11, Issue:18
Selective, orally active MMP inhibitors with an aryl backbone.
AID107185Inhibition of gelatinase-A (Matrix metalloprotease-2)1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.
AID104909Inhibition of matrilysin (Matrix metalloprotease-7)1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.
AID107333In vitro selective inhibition against matrix metalloprotease-2 (MMP-2) using fluorimetric assay2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
AID108749Inhibitory activity against MMP-1 (Matrix metalloprotease-1)1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.
AID1609033Inhibition of recombinant human MMP2 using thiopeptide as substrate preincubated for 30 mins followed by substrate addition and measured every mins for 20 min by colorimetric assay
AID108894Inhibitory activity against matrix metalloprotease-1 (MMP1)2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.
AID440472Half life in rat at 20 mg/kg, iv2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Hydroxamates: relationships between structure and plasma stability.
AID10876650 percent inhibition of human Matrix metalloprotease-1 by the cleavage of fluorogenic peptide MCA-Pro-Leu-Gly-Leu-Dpa-ala-Arg-NH22000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and activity of selective MMP inhibitors with an aryl backbone.
AID1609038Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
AID107847Inhibition of neutrophil collagenase (Matrix metalloprotease-8)1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.
AID108140Inhibition of Matrix metalloprotease-92001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.
AID249410Ratio of IC50 value for MMP2 and MMP72005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.
AID233120Relative affinity for MMP-2 over MMP-12004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.
AID1609036Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
AID249408Ratio of IC50 value for MMP2 and MMP12005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.
AID107182Inhibition of human matrix metalloprotease-22002Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19
Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.
AID732018Antitumor activity against mouse LLC cells allografted in mouse assessed as primary tumor growth inhibition2013European journal of medicinal chemistry, Feb, Volume: 60Sulphonamides: Deserving class as MMP inhibitors?
AID107502Inhibition of Matrix metalloprotease-32001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.
AID107361In vitro inhibitory activity against matrix metalloprotease-3.1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.
AID1609039Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
AID108147Inhibitory activity against matrix metalloprotease-9 (MMP9)2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.
AID209356Selective inhibition of the cellular TNF alpha release from LPS-stimulated THP-1 cells2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
AID109581In vitro inhibitory activity against gelatinase-A (matrix metalloprotease-2).1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.
AID107693In vitro inhibitory activity against matrilysin (matrix metalloprotease-7).1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.
AID732017Antitumor activity against mouse LLC cells allografted in mouse assessed as secondary tumor growth inhibition2013European journal of medicinal chemistry, Feb, Volume: 60Sulphonamides: Deserving class as MMP inhibitors?
AID215431Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.
AID108758Inhibition of Matrix metalloprotease-12001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.
AID241643Inhibition of human matrix metalloprotease-92005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1345409Human MMP13 (M10: Matrix metallopeptidase)2005Medicinal chemistry (Shariqah (United Arab Emirates)), Jan, Volume: 1, Issue:1
Protease inhibitors in the clinic.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (93)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's11 (11.83)18.2507
2000's60 (64.52)29.6817
2010's12 (12.90)24.3611
2020's10 (10.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.59 (24.57)
Research Supply Index4.63 (2.92)
Research Growth Index4.89 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (5.15%)5.53%
Reviews15 (15.46%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other77 (79.38%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Double-Blind, Placebo-Controlled Phase II Study of the Matrix Metalloprotease Inhibitor Prinomastat in Combination With Temozolomide Following Radiation Therapy in Patients Having Newly Diagnosed Glioblastoma Multiforme [NCT00004200]Phase 20 participants Interventional1999-10-31Completed
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Matrix Metalloprotease Inhibitor AG3340 in Combination With Mitoxantrone and Prednisone With Provision for Subsequent Change in Therapy in Patients Having Hormone-Refractory Prostate C [NCT00003343]Phase 3525 participants (Anticipated)Interventional1998-03-31Completed
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Matrix Metalloprotease Inhibitor Prinomastat (AG3340) in Combination With Gemcitabine and Cisplatin in Patients Having Advanced Non-Small Cell Lung Cancer [NCT00004199]Phase 30 participants Interventional1999-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]